Plexxikon

Biotech

Daiichi axes Plexxikon R&D facility to free up cash for ADC work

More than 10 years after buying the biotech for $805 million upfront, Daiichi has decided to drop the 60-employee operation to focus on ADCs.

Nick Paul Taylor Jan 12, 2022 7:30am

Daiichi's biotech unit Plexxikon signs away BRAF cancer drug

Jun 3, 2020 10:00am

Daiichi Sankyo

UPDATED: Daiichi’s ‘breakthrough’ PhIII trial suspended to new patients

Oct 19, 2016 4:39am